EPi- Sense ST Coagulation System
AtriCure, Inc. · Decision date Sep 24, 2026
What did the FDA decide?
FDA records P200002/S015 as a supplement to PMA P200002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 24, 2026.
FDA approval order statement
an alternate sterilization cycle
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200002/S015
- Regulatory pathway
- PMA supplement
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- Decision code
- OK30
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200002 · Original PMA
EPi-Sense Guided Coagulation System
P200002/S015 received
Application receipt date recorded by FDA.
P200002/S015 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P200002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| AtriCure, Inc. | PMA approval | Apr 28, 2021 | FDA |
Explore the linked device profile
Other records with product code OCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy Ablation SystemP100046/S021 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| AtriCure, Inc. | PMA approval | Dec 14, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AtriCure, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7555 Innovation Way, Mason, OH, 45040
Sources and methodology
- Original FDA record: P200002/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

